Climb Bio CLYM
NASDAQ CLYM
$11.07 -0.40 (-3.49%)
At close: Oct 1, 2026 · 4:00 PM EDT

Climb Bio (CLYM) Preferred Stock Liabilities (2020 - 2021)

Updated

Climb Bio's Preferred Stock Liabilities was $152.76 million in Q2 2021, up 464.4% from $27.07 million a year earlier and up 64.6% from the prior quarter.

Analysis

Climb Bio (CLYM) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, Preferred Stock Liabilities at Climb Bio came in at $46.55 million.

  • Per Business Quant data, CLYM's Preferred Stock Liabilities in the three quarters before Q2 2021 was $92.8 million (Q1 2021), $46.55 million (Q4 2020) and $27.53 million (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Climb Bio 873.49 Mn 873.49 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 152.76 Mn
Mar 31, 2021 92.80 Mn
Dec 31, 2020 46.55 Mn
Sep 30, 2020 27.53 Mn
Jun 30, 2020 27.07 Mn
API Access

Climb Bio Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CLYM&period=max&api_key=YOUR_API_KEY